Is Eli Lilly a Millionaire Maker?
Pharmaceutical maker Eli Lilly (NYSE: LLY) has seen its share price rocket higher by over 500% over the past five years. That stands in stark contrast to a roughly 20% advance for competitor (NYSE: MRK) and a nearly 30% decline for (NYSE: PFE). There's one very big story supporting Eli Lilly's stock price advance, but investors need to consider some drug industry facts before they invest today.
The big news over the past five years for pharmaceutical giant Eli Lilly was its weight loss drug success. It has a leading position in the new class of drugs known as GLP-1 inhibitors. This is a very big deal, given the prevalence of obesity and the ongoing health risks faced by people struggling with their weight. On top of that, there's a beauty angle here that can't be ignored, which further expands the market for GLP-1 drugs.
Image source: Getty Images.
Source Fool.com
Pfizer Inc. Aktie
Leichte Buy-Präferenz bei der Pfizer Inc. Aktie.
Ein positives, wenn auch nicht starkes, Potenzial für Pfizer Inc. mit einem Kursziel von 27 € im Vergleich zu 23.0 €.
